Evotec SE announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI…
SOPHiA GENETICS announced a new global collaboration to develop, validate, and deploy two companion diagnostics supporting precision oncology therapies with AstraZeneca. This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GEN…
Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, announced the successful closing of its acquisition of Catalent's Nottingham, UK facility. With the transaction now complete, Codis …
Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising precl…
Quasar Medical, a global contract development and manufacturing organization (CDMO) specializing in minimally invasive medical devices, announced the acquisition of the Medres' Nitinol Design and Development Center in San Diego, California, today. The acquisition significantly expands Quasar's capabilities in advanced…
CREATE Medicines, Inc, a clinical-stage biotechnology company pioneering in vivo immune programming, announced a strategic research collaboration with Australia's Monash University and its world-leading Monash Institute of Pharmaceutical Sciences (MIPS). The partnership broadens CREATE's portfolio by accessing Monash'…
Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, announced the closing of a $70 million Series C financing. The financing included strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb, …
Kaigene, Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced that it has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho"), a leading Japanese pharmaceutical company, for the exclusive development and …
IMPACT Therapeutics is pleased to announce that it has entered into an exclusive partnership with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pharma to bring innovative specialty medicines to patients, to grant Pharmanovia the exclusive rights to manufacture,…
Ember LifeSciences, Inc., an award-winning provider of advanced pharmaceutical cold chain solutions, has entered into a capital and business alliance with Alfresa Corporation "Alfresa", a subsidiary of Alfresa Holdings Corporation. The Alfresa Group has the No. 1 domestic net sales in the pharmaceutical wholesale bus…
Page 4 of 40